SMS Reminders Moderately Effective for Flu Vaccination

This article originally appeared here.
Share this content:
SMS Reminders Moderately Effective for Flu Vaccination
SMS Reminders Moderately Effective for Flu Vaccination

MONDAY, Nov. 20, 2017 (HealthDay News) -- Short message service (SMS) reminders are a moderately effective way to increase the rate of influenza vaccination among high-risk patients, according to a study published in the November/December issue of the Annals of Family Medicine.

Annette K. Regan, Ph.D., M.P.H., from Curtin University in Western Australia, and colleagues conducted a randomized trial of SMS reminders for influenza vaccination. A total of 12,354 eligible high-risk patients who had a mobile telephone number on record at 10 practices were randomized to receive a vaccination reminder by SMS (intervention) or to receive no SMS (control). Vaccination data were extracted from the patients' electronic medical records about three months after the SMS was sent.

The researchers found that 12 percent of the 6,177 participants in the intervention group and 9 percent of the 6,177 participants in the control group were vaccinated during the study period (relative increase attributable to SMS, 39 percent). One additional high-risk patient was immunized for every 29 SMSs sent, costing $3.48. The effect was greatest for children aged younger than 5 years, with parental receipt of an SMS reminder associated with a more than twofold increase in the likelihood of parents having their child vaccinated (relative risk, 2.43).

"We found SMS reminders to be a modestly effective, low-cost means to increase seasonal influenza vaccine coverage among high-risk patients," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »